

The use of total funds channelled through “la Caixa” to Gavi programmes in 2021

Final Report to the “la Caixa”
Foundation (for Gavi)

March 2022



Executive summary

The “la Caixa” Foundation and GAVI partnership is aimed at protecting the lives of the world’s most disadvantaged children, with a specific focus on providing life-saving protection against pneumonia by funding pneumococcal vaccine.

Thanks to the generosity of the “la Caixa” Foundation, “la Caixa” employees, the Business Alliance for Child Vaccinations, and microdonations from the Spanish public, the Bill & Melinda Gates Foundation (BMGF) have matched your funds to thus double the impact.

In 2021, the La Caixa-BMGF partnership has channeled over USD 7.459.893,18 to Gavi and contributed funds to vaccinate an estimated 1M children with pneumococcal vaccine in total – hence sponsoring 44% of the Pneumo-Ethiopia programmes, as well as resulting in sponsoring 100% of the Pneumo-Mozambique programmes for the year.

Table of content

- 1. Overview of use of “la Caixa” funds in 2021**
- 2. Background information on Pneumonia and Ethiopia**
- 3. Gavi Matching Fund report**

1

Overview of use of "la Caixa" funds in 2021*

4 * Please note that Gavi and La Caixa signed a new agreement starting as of 2021. This specific report reflects contributions only made under the new agreement.

La Caixa's contributions and impact in 2021

“la Caixa” Contributions:

- “la Caixa” Foundation:
 - EUR 1.642.115,63
 - USD 1.861.857,89
- Business Alliance:
 - EUR 1.538.640,44
 - USD 1.752.755,25
- Employees & Microdonations:
 - EUR 103.475,19
 - USD 115.333,45

Total:

- EUR 3.284.231,26
- USD 3.729.946,59

So far, the Gavi Matching Fund increased your contributions with **EUR 3.2M**
USD 3.7M

from the
Bill&Melinda
Gates Foundation



Projected Impact:

- 2,497,612* doses of pneumococcal vaccine were purchased
- Approximately 1,000,000 children * immunized

5 * These numbers do not include the 10% wastage. Total includes possible indicative number of doses purchased with La Caixa Funds (only).

Detailed breakdown of la Caixa Funds for pneumococcal vaccines and impact

Use of funds and impact in Ethiopia & Mozambique				Total
	"la Caixa" Foundation**	Employees & Microdonations**	Business Alliance**	Investment amount
Funds (Amounts)	EUR 1.642.115,63 USD 1.861.857,89	EUR 103.475,19 USD 115.333,45	EUR 1.538.640,44 USD 1.752.755,25	EUR 3.284.231,26 USD 3.729.946,59
Funds (%)	50%	3%	47%	100%
Doses purchased	623,360	38,614	586,832	1,248,806
Children immunized	250,000	16,000	240,000	506,000*

*These numbers include a 10% wastage. Total includes possible indicative number of doses purchased with La Caixa Funds (only).

** These figures are reported by la Caixa and not validated by Gavi.

Note: All impact calculations are estimates. Adjustments from the preliminary report, as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

Detailed breakdown of funds matched by the Bill&Melinda Gates Foundation (**Matching Fund under new agreement**)

Year	Funding Source	Country	Vaccine	Funds matched (%)	Funds matched (USD)	Doses Purchased	Children Immunized
2021	Total “la Caixa” Investment	Ethiopia	Pneumococcal	100%	3.729.946,59	1,248,806	506,000
2021	“la Caixa” Foundation	Ethiopia	Pneumococcal	100%	1.861.857,89	623,360	250,000
2021	Employees and Microdonations	Ethiopia	Pneumococcal	100%	115.333,45	38,614	16,000
2021	Business Alliance	Ethiopia	Pneumococcal	100%	1.752.755,25	586,832	240,000

**Keep in mind that these numbers include the usual 10% wastage.*

Total includes possible indicative number of doses with La Caixa Funds (only). These figures are reported by la Caixa and not validated by Gavi.

Use of “la Caixa” Foundation funds corresponding to the contributions in 2021

FINANCIAL STATEMENT ON FUNDS UTILIZATION LA CAIXA FUNDS - 2021 CONTRIBUTION

Details of contributions received, funds allocated to Gavi programmes, and the balance of contribution

Table 1: 2021 Contributions received as of 25 February 2022

Description or reference	Date of contributions received by Gavi	Amount of contribution received in US\$
2021 Funding from La Caixa Foundation	09 November 2021	1,145,000
2021 Funding from Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	11 February 2022	832,191
2021 Funding from Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	14 February 2022	1,752,755
Total 2021 contributions received as of 25 February 2022		3,729,947

Note 1

Table 2: Funds allocated to Gavi programmes as of 31 December 2021

Programme description	Implementing country	Number of doses of vaccines	Date of fund allocations	Amount of funds allocated in US\$
Pneumococcal Programmes (CTN 2021-644)	Ethiopia		19 May 2021	3,182,714
Total funds allocated to Gavi programmes as of 31 December 2021		1,097,487		3,182,714

Note 2

Note 1

Table 3: Balance of contribution as of 31 December 2021

Description	Amount in US\$
Total 2021 contributions received, per Table 1 above	3,729,947
Total funds allocated to Gavi programmes, per Table 2 above	(3,182,714)
Balance of 2021 contribution as of 31 December 2021	547,233

Note 3

Notes:

- This Financial Statement includes all funding received through to 15 February 2022 to fully reflect the entire of La Caixa's 2021 contribution, while funding allocations have only been performed through to 31 December 2021, at the time of preparation of this Financial Statement.
- A portion (US\$ 5,318,020) of CTN 2021-644 was sponsored by La Caixa; with US\$ 3,182,713.64 covered by La Caixa's 2021 contribution, while the remaining US\$ 2,135,306.36 is anticipated to be covered by La Caixa's 2022 contribution (yet to be received).
A portion (US\$ 495,009.70) of an additional programme, i.e., CTN 2022-016 paid on 3 Nov 2021, was also allocated to La Caixa in anticipation of La Caixa's 2022 contribution (yet to be received).
- This represents funding raised by the La Caixa during Q1 2021 of EUR 481,037 (equivalent value in US\$ of US\$ 547,232.95), that has yet to be spent on pneumococcal vaccines for Mozambique.

The total contributions for 2021 are EUR 3.284.231

“la Caixa” Foundation	EUR 1.642.115,63
Business Alliance:	EUR 1.538.640,44
857 Companies	EUR 1.188.260,73
1 098 Private banking donations	EUR 350.379,71
Employees & Microdonations:	EUR 103.475,19
599 Employees	EUR 38.848,00
19 302 Microdonations	EUR 64.627,19

2

Background information on Pneumonia and Ethiopia

The challenge: pneumonia and pneumococcal vaccine

Streptococcus pneumoniae, commonly known as pneumococcal disease, is the leading cause of pneumonia – the world's number one killer of children under five years of age.

According to UNICEF*, Pneumonia kills more children than any other infectious disease, claiming the lives of over 800,000 children every year, or around 2,200 every day. Progress in reducing deaths due to pneumonia in children under five has been significantly slower than for other infectious diseases. Since 2000, under-five deaths due to pneumonia have declined by 54%.


Additional risks to children's health and wellbeing surged during the pandemic, with COVID19 causing disruptions throughout the health system as well as to the lives of families. In areas where health personnel have become overstretched, key commodities (such as oxygen treatment) have become short in supply, or where care-seeking behaviors have been reduced due to transmission mitigation efforts (e.g. lockdowns, travel restrictions), this could result in more severe illness and higher mortality from pediatric pneumonia.

The most effective way to prevent these deaths is to ensure that all children have access to safe, affordable vaccines.

To accelerate the development and production of a new generation of pneumococcal vaccines, more targeted at the needs of developing countries and more affordable, GAVI, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009. The PCV AMC sunset at the end of 2020, and included one new eligible PCV, Pneumosil by the Serum Institute of India, at a 30% cheaper price per dose than the older two vaccine options.

The challenge: pneumonia and pneumococcal vaccine

Deaths of children under five by infectious disease, 2000 vs 2018



Source: UNICEF analysis based on WHO and Maternal and Child Epidemiology Estimation Group interim estimates produced in September 2019, applying cause of deaths for the year 2017 to United Nations Inter-agency Group for Child Mortality Estimation estimates for the year 2018.


Country Profile: Ethiopia 1/2

Total population (2020)	114,963,588
Birth cohort (2021)	3,654,995
Surviving Infants (surviving to 1 year per year, 2021)	3,539,482
Infant mortality rate (deaths < 1 year per 1000 births, 2019)	37/1000
Child mortality rate (deaths < 5 years per 1000 births, 2019)	51/1000
World Bank Index, IDA (2019)	3.47
Gross Nation Income (per capita US\$, 2020)	890
No. of districts/territories (2020)	975



Country Profile: Ethiopia 2/2

DTP3 - WHO/UNICEF estimates (2019)	69%
DTP3 - Official country estimates (2020)	99%
Household survey: Last DTP3 survey (2017)	61%
% districts achieving > 80% DTP3 coverage (2020)	77%
% districts achieving < 50% DTP3 coverage (2020)	4%
MCV WHO/UNICEF estimates (2020)	60%




Country Profile: Mozambique 1/2

Total population (2020)	31,255,435
Birth cohort (2021)	1,174,284
Surviving Infants (surviving to 1 year per year, 2021)	1,118,455
Infant mortality rate (deaths < 1 year per 1000 births, 2019)	55/1000
Child mortality rate (deaths < 5 years per 1000 births, 2019)	74/1000
World Bank Index, IDA (2019)	3.14
Gross Nation Income (per capita US\$, 2020)	460
No. of districts/territories (2020)	161



Country Profile: Mozambique 2/2

DTP3 - WHO/UNICEF estimates (2019)	88%
DTP3 - Official country estimates (2020)	108%
Household survey: Last DTP3 survey (2014)	82%
% districts achieving > 80% DTP3 coverage (2020)	95%
% districts achieving < 50% DTP3 coverage (2020)	2%
MCV WHO/UNICEF estimates (2020)	81%



3

Gavi Matching Fund Report

Use of the Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channeled through “la Caixa” in 2021

Use of Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channeled through “la Caixa” in 2021

FINANCIAL STATEMENT ON FUNDS UTILIZATION

GATES MATCHING FUNDS FOR LA CAIXA - 2021 CONTRIBUTION

Details of contributions matched, funds allocated to Gavi programmes, and the balance of contributions matched

Table 1: 2021 Contributions matched, and to be matched, by the Gates Matching Fund as of 25 February 2022

Description or reference	Amount of contribution matched in US\$
Gates Matching Funds for 2021 Funding from La Caixa Foundation	1,145,000
Anticipated Gates Matching Funds for 2021 Funding from La Caixa Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	2,584,947
Total 2021 contributions matched, and to be matched, by the Gates Matching Fund as of 25 February 2022	3,729,947 Note 1

Table 2: Funds allocated to Gavi programmes as of 31 December 2021

Programme description	Implementing country	Date of fund allocations	Amount of funds allocated in US\$
Pneumococcal Programmes (CTN 2021-644)	Ethiopia	19 May 2021	43,000
Pneumococcal Programmes (CTN 2022-016)	Ethiopia	16 July 2021	3,326,040
Pneumococcal Programmes (CTN 2022-016)	Ethiopia	03 November 2021	360,907
Total funds allocated to Gavi programmes as of 31 December 2021			3,729,947 Note 1

Table 3: Balance of contributions matched as of 31 December 2021

Description	Amount in US\$
Total 2021 contributions matched, and to be matched, per Table 1 above	3,729,947
Total funds allocated to Gavi programmes, per Table 2 above	(3,729,947)
Balance of 2021 contributions matched, and to be matched, as of 31 December 2021	0

Notes:

- This Financial Statement includes all funding matched, as well as to be matched, by the Gates Matching Fund on La Caixa's 2021 contribution through to 25 February 2022, while funding allocations have only been performed through to 31 December 2021, at the time of preparation of this Financial Statement.
- A portion (US\$ 2,443,990) of CTN 2022-016 was sponsored by the Gates Matching Fund on La Caixa; with US\$ 360,907 covered by the Gates Matching Fund on La Caixa's 2021 contribution, while the remaining US\$ 2,083,083 is anticipated to be covered by Gates Matching Fund on La Caixa's 2022 contribution (yet to be matched).

Thank You!

